特定非営利活動法人日本オスラー病患者会 News Releases

HHT/Hereditary Hemorrhagic Telangiectasia: Hemostatic Agent 'SurgeCell' Gains Additional Indication Approval for Severe Epistaxis — A Major Step Forward Driven by 20,000+ Signatures and Patient-Led Advocacy

On May 13, 2024, the hemostatic agent 'SurgeCell' received approval for an expanded indication to tr… · 2026-06-16

First Osler's Disease (HHT) Learning Exchange Event in Hiroshima to be Held on July 26, 2026

日本オスラー病患者會將於2026年7月26日在廣島舉辦首場罕見疾病「奧斯勒病（HHT）」學習交流會，旨在提高僅10%的診斷率並促進醫療協作。 · 2026-05-12

[First time in Hiroshima Prefecture] Learning Exchange Meeting for Patients, Families, and Medical Professionals on Osler-Weber-Rendu Disease (HHT), a Designated Intractable Disease 227 with a 10% Diagnosis Rate, to be Held on July 26, 2026

The Japan HHT Patients Association will hold its first learning exchange meeting in Hiroshima Prefec… · 2026-05-12